Baxter International and Momenta Pharmaceuticals have entered into biosimilars development and commercialization collaboration. Baxter will leverage its clinical development and biologic manufacturing expertise, as well as its sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development. Baxter will make an upfront cash payment of $33 million to Momenta related to the collabor...